Monthly research recap
Psilocybin research: June 2026
What June 2026's 25 new studies found, synthesized from the papers below. All Psilocybin research →
The synthesis
Synthesized from 15 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, then ranked by relevance.
Research on psilocybin in June 2026 shows promising but preliminary therapeutic effects for depression, OCD, and PTSD, with evidence of rapid symptom reduction and neuroplasticity. However, results are mixed regarding durability, with benefits often limited to weeks or months, and microdosing studies show no significant mood or cognitive improvements. Key caveats include small sample sizes, short follow-up periods, and challenges with blinding.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 | preclinical | No effect | Chronic psilocin microdosing did not affect behavior or dentate gyrus cell proliferation in rats. | |
| Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations. 2026 | review | Supports | Psilocybin-assisted therapy shows short-term improvement in TRD symptoms persisting for weeks to months. | |
| Phase 1 trial suggests benefit of psilocybin in OCD treatment 2026 | Phase 1 trial | 15 | Supports | Repeated high-dose psilocybin was more effective than low-dose or placebo in reducing OCD symptoms. |
| Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex. 2026 | preclinical | Supports | Psilocybin reduced fear memory and restored neuroplasticity in hippocampus and mPFC in mice. | |
| Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis 2026 | umbrella review | 1614 | Mixed | Microdosing showed a small decrease in cognitive control and no significant mood effects. |
| Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram 2026 | observational | Supports | Psilocybin increased brain network reconfiguration under perturbation, suggesting greater brain flexibility. | |
| Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test 2026 | preclinical | Supports | Blocking 5-HT2B receptors abolished psilocybin's antidepressant-like effects in the forced swim test. | |
| Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats. 2026 | preclinical | Supports | Psilocybin reversed anhedonia, produced antidepressant and anxiolytic effects, and induced hippocampal neurogenesis. | |
| Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes 2026 | RCT reanalysis | Mixed | Women on psilocybin showed greater anxiety reduction than men, but sex differences were small for other outcomes. | |
| Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence 2026 | review | Supports | Psilocybin-assisted therapy produces rapid remission in TRD, but durability beyond weeks is uncertain. | |
| Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin. 2026 | preclinical | Supports | 5-HT2A receptor signaling in layer 5 pyramidal neurons is necessary for psilocybin-induced synaptic remodeling but not for head-twitch response. | |
| Safety, Efficacy, and Blinding Integrity of Psilocybin-Assisted Therapy for Substance Use Disorders: A Systematic Review of Randomized Controlled Trials 2026 | systematic review | Unclear | Review of RCTs on psilocybin for SUDs is ongoing, with focus on efficacy, safety, and blinding integrity. | |
| PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW 2026 | review | Supports | Psilocybin-assisted therapy shows rapid onset and long-term benefits up to 6–12 months for depression. | |
| The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential. 2026 | narrative review | Mixed | Psychedelics can exacerbate psychosis in vulnerable individuals, but potential therapeutic applications exist for stable patients. | |
| How sex and environmental conditions shape psilocybin's effects on social and cognitive function in mice 2026 | preclinical | Mixed | Psilocybin's effects on social behavior varied by sex: females became more social, males showed reduced stress behaviors. |
Points of agreement
- Psilocybin shows rapid antidepressant and anxiolytic effects in both preclinical and clinical studies.
- Psilocybin promotes neuroplasticity, including hippocampal neurogenesis and synaptic remodeling.
- Microdosing does not produce significant mood or cognitive benefits in controlled studies.
Conflicts
- Some reviews report long-term benefits up to 6–12 months, while others note uncertain durability beyond weeks.
- Sex-specific effects vary: one study found greater anxiety reduction in women, another found sex differences in social behavior in mice.
- The role of 5-HT2B vs 5-HT2A receptors in mediating therapeutic effects is debated.
Gaps
- Long-term durability of psilocybin effects beyond several months is not well established.
- Blinding integrity in RCTs is a major concern, with limited formal assessment.
- Studies lack adequate comparisons with established treatments like esketamine or ECT.
- Research on psilocybin for substance use disorders is still dominated by non-RCT designs.
- Safety and efficacy in vulnerable populations (e.g., schizophrenia, adolescents) remain understudied.